
This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.

This study measured the value of survival gains attributable to the introduction of 3 novel therapies for myelodysplastic syndromes.

Published: January 16th 2017 | Updated:

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
